100707-39-9

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2-methyl-4-pyrimidinecarboxylic acid is used as a building block for the synthesis of various organic compounds. Its unique structure allows for the formation of a wide range of derivatives, making it a valuable intermediate in the preparation of complex molecules.
Used in Pharmaceutical Industry:
5-Bromo-2-methyl-4-pyrimidinecarboxylic acid is used as a key intermediate in the development of new pharmaceuticals. Its presence in the molecular structure of certain drugs contributes to their therapeutic properties, such as antimicrobial, antiviral, or anticancer activities. 5-Bromo-2-methyl-4-pyrimidinecarboxylic acid's versatility in chemical reactions enables the creation of novel drug candidates with improved efficacy and reduced side effects.
Used in Research and Development:
5-Bromo-2-methyl-4-pyrimidinecarboxylic acid is used as a research tool in academic and industrial laboratories. Its reactivity and structural features make it an ideal candidate for studying the mechanisms of various chemical reactions and exploring new synthetic pathways. This knowledge can be applied to the development of innovative materials and therapeutic agents.

InChI:InChI=1/C6H5BrN2O2/c1-3-8-2-4(7)5(9-3)6(10)11/h2H,1H3,(H,10,11)

Upstream product

• 488-11-9 mucobromic acid 
• 124-42-5 acetamidine hydrochloride 
• 90994-06-2 (2E)-2,3-dibromo-4-oxobut-2-enoic acid 
• 766-38-1 mucobromic acid 

Downstream Products

• 1240783-02-1 (5-bromopyrimidin-2-yl)methylamine 
• 1235451-38-3 tert-butyl (5-bromopyrimidin-2-yl)methylcarbamate 
• 1193116-74-3 5-bromo-2-(bromomethyl)pyrimidine 
• 311335-73-6 5-Bromo-2-methyl-pyrimidine-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide 
• 113949-10-3 5-methoxy-2-methylpyrimidine-4-carboxylic acid 
• 7752-78-5 5-bromo-2-methylpyrimidine 
• 7496-32-4 6-methyl-1H-pyrimido[5,4-d]pyrimidine-2,4-dione 
• 99989-21-6 5-anilino-2-methyl-pyrimidine-4-carboxylic acid 
• 311335-74-7 5-Bromo-2-methyl-pyrimidine-4-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide 
• 311334-73-3 2-Methyl-5-phenyl-pyrimidine-4-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide 

Relevant academic research and scientific papers

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.